Ipca Laboratories Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Ipca Laboratories Ltd trades at ₹1,734, in a confirmed uptrend and 32 weeks into that stage. That is +10.2% against its own 200-day average. It sits at 74% of a 52-week range of ₹1,269 to ₹1,901. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 13 straight weeks.

Today the stock is in a confirmed uptrend — week 32 of stage 2, confirmed. At ₹1,734 it trades +10.2% versus its 200-day average and sits at 74% of its 52-week range (₹1,269–₹1,901).

Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +501% while the NIFTY 500 moved +276% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 13 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

Story check

Ipca Laboratories Ltd's story is not scored yet against the markers our research file set on 19 July 2026. Where it sits in its own cycle: MID_CONTRACTION. Our fortnightly research layers last read it on 19 July 2026.

Our read, 19 July 2026. Domestic chronic compounder with FY26 PAT +51% and margin now at 21% OPM — overhang is Unichem Ireland savings slip (fifth guidance inconsistency), now cleared for FY27.

From the numbers. PE at 62.8th percentile of 10-year history — the trailing PE 40.9 reflects earnings growth from Rs 1141 Cr (FY21 TTM PAT) to Rs 1185 Cr (FY26). Cycle is EARNINGS_DRIVEN: EPS rose 64% in 8 quarters while PE compressed…

From the price. Price stage 2, week 32 — above its 200-day line, relative strength rising.

From the research. Domestic chronic compounder with FY26 PAT +51% and margin now at 21% OPM — overhang is Unichem Ireland savings slip (fifth guidance inconsistency), now cleared for FY27.

🚨 Where they disagree. PE at 62.8th percentile of 10-year history — the trailing PE 40.9 reflects earnings growth from Rs 1141 Cr (FY21 TTM PAT) to Rs 1185 Cr (FY26). Cycle is EARNINGS_DRIVEN: EPS rose 64% in 8 quarters while PE compressed 39% from the Sep 2024 peak at 67.4x. Normalized PE per cycle_normalized is 52.4 (80th %ile) because OPM is currently above mid-cycle (20.3% vs normalized 18.3%). Cycle_normalized verdict: FAIRLY_PRICED. This is not a depressed-valuation entry; it is a quality compounder at mid-cycle pricing where the thesis depends on continued execution, not on multiple mean-reversion.

What is proven. Domestic chronic compounder with FY26 PAT +51% and margin now at 21% OPM — overhang is Unichem Ireland savings slip (fifth guidance inconsistency), now cleared for FY27.

What is not proven yet. Domestic formulation growth falls below 8% YoY for two consecutive quarters (invalidating the chronic mix shift thesis), OR FY27 consolidated EBITDA margin fails to reach 22% despite guided price increases (proving the input cost pass-through is weaker than management claims), OR Unichem EBITDA margin stays below 10% by Q3 FY27 (a fifth timeline slip with no credible new mechanism).

🚨 What would change our mind. Domestic formulation growth falls below 8% YoY for two consecutive quarters (invalidating the chronic mix shift thesis), OR FY27 consolidated EBITDA margin fails to reach 22% despite guided price increases (proving the input cost pass-through is weaker than management claims), OR Unichem EBITDA margin stays below 10% by Q3 FY27 (a fifth timeline slip with no credible new mechanism).

Layer 1 read, 19 July 2026 — KEEP. Chronic-pharma compounder with a genuine earnings-led multiple compression — OPM up four straight years while the PE fell. OPM has expanded structurally from 15% to 21% over four years and FY26 PAT rose 50.8%, yet the PE has compressed to 40.9, down 52% from its peak, WHILE EPS climbs (eps_8q +64%, multiple_8q -39%) — the textbook depressed-breakout with STRONG cash conversion (OCF/PAT 1.37). The RED 'paper profits' flag resolves cleanly: other income is only 7-11% of PBT and the two weak PAT quarters were one-off depressed, so this is real operating leverage, not accounting.

What would change Layer 1’s mind. Domestic formulation growth falls below 8% YoY for two consecutive quarters (breaks the chronic-mix thesis) OR FY27 consolidated EBITDA margin fails to reach 22% despite guided price hikes OR Unichem margin stays below 10% into Q3 FY27 (a sixth guidance slip) — any would convert the earnings-led story into a stalled re-rating.

Layer 2 read, 19 July 2026 — ADVANCE. Domestic chronic compounder that is cheap versus its own re-rated sector, and the sector's expansion is paid for by real earnings. IPCALAB's profit is growing on a genuine four-year margin ramp (operating margin 15%->21%, profit +51%) with strong cash conversion, and its valuation is only mid-range (49th percentile, +30% margin of safety) — unusually cheap for a Gold-tier name. The external check strengthens the case: its pharma-formulator sector is a top-focus sector whose gains were driven by real earnings, not multiple hype (sector profit up ~78% vs multiple up only ~13%), and the fund's own second-order work puts compliance-heavy formulation leaders like IPCALAB on the winning side of pharma's regulatory split. The one watch item — Unichem's repeatedly-slipped Ireland savings — is a management-credibility flag now…

What would change Layer 2’s mind. Domestic formulation growth falls below IPM for two consecutive quarters (chronic mix-shift plateau), OR Q1 FY27 Unichem EBITDA margin stays below 9% (a fifth timeline slip with no new mechanism), OR the sector print rolls over — aggregate SigmaPAT flat/negative while OPM slips off its decade-high — any external roll-over would flip ADVANCE toward DROP.

Layer 3 read, 19 July 2026 — DEPLOY. Clean pharma leader — guidance misses are quarantined in the US sub, core business delivered and de-levered. The one HIGH-severity Timeline risk is Unichem US margin (12%->8%), but it is a subsidiary problem the standalone domestic franchise covers — FY26 consolidated PAT rose 50.8% to Rs 1184 Cr and management cut borrowings by Rs 554 Cr from operating cash. Promoter stayed at 46.3% and there are no red flags, so this is a contained margin-recovery risk, not a management-integrity risk. Only real portfolio risk is FY27 API/solvent input inflation outrunning 6-7% pricing, which the 100% API cost pass-through neutralizes.

What would change Layer 3’s mind. A Q1 FY27 print showing the CORE domestic branded business missing its 12-13% growth guide (not just Unichem), or a fresh SEBI/USFDA enforcement action — either would move the credibility problem from the subsidiary to the franchise and flip DEPLOY toward BENCH.

The test written in advance. FY27 Input Cost Inflation Exceeds Pricing Power — FY27 Input Cost Inflation Exceeds Pricing Power Q1 FY27 material cost-to-sales ratio (must stay below 26.5% to confirm management's offset thesis) by the next result.

The test written in advance. Unichem US Structural Deterioration Beyond One-Quarter Recovery — Unichem US Structural Deterioration Beyond One-Quarter Recovery Q1 FY27 Unichem EBITDA margin (must show improvement above 9%); contract win announcements on 2-3 key molecules by the next result.

What the company does. FY26 consolidated revenue Rs 9599 Cr (+8% YoY) and PAT Rs 1184 Cr (+51% YoY) — driven by domestic chronic mix shift, material cost deflation of 336 bps, and API re-acceleration to 10% growth. Q4 FY26 standalone EBITDA margin +408 bps to 25.27%; FY27 consolidated guidance 12-13% revenue growth, EBITDA margin targeting 22-22.3% — limited by 10-12% input cost inflation partially offset by 6-7% price increases. Unichem Ireland overhead (EUR 4-5M annually) now closes in FY27; US market share recovery in progress; Pisgah Labs formulation facility commissioning targeted Q4 FY27 for FY28 revenue.

🚨 What the surface reading misses. The surface reading is: PAT Rs 64 Cr in Mar 2025 (vs Rs 364 Cr in Dec 2025) looks like earnings collapse The research reads it further: Negative other_income of -Rs 179 Cr in Mar 2025 and -Rs 118 Cr in Mar 2024 are below-the-operating-line EU competition penalty provisions at Unichem — operating profit in both quarters was Rs 322-429 Cr (the operating trajectory is intact). The -Rs 179 Cr one-off accounted for 140% of the PBT figure.

🚨 What the surface reading misses. The surface reading is: FY26 OCF/PAT 0.96 — below 1.0 looks like weak cash quality The research reads it further: The 3-year aggregate is 1.37 — cash quality is genuinely above PAT. The FY26 dip to 0.96 is explained by a one-year Rs 460 Cr WC build (delta_wc = Rs 460 Cr, the largest in the 5-year series). Inventory days rose from 336 to 353 (Unichem transit mode shift from air to sea extends in-transit inventory); debtor days stable at 77; payable days improved from 111 to 122 (better payables management). Cash story: 'one_off_drain' — the concall context confirms this is transit-mode-driven, not a structural receivables buildup.

Lever 1 · Operating leverage — BUILDING. FY26 domestic Rs 3817 Cr (+10% YoY); chronic now 35% of domestic mix (market at 40%); CNS +19%, dermatology +22%, cardiovascular +16% in FY26. What proves it keeps working: Domestic Chronic Outperformance and Mix Shift. It stops working if Domestic formulation growth falls below IPM for two consecutive quarters, signaling chronic market share gains have plateaued or competitive disruption in CNS/dermatology segments.

Lever 2 · Value-added mix — BUILDING. FY26 material cost-to-sales improved 336 bps (9M); FY27 faces 10-12% input inflation (paracetamol, metformin, solvents) partly offset by 6-7% price increases on decontrolled products. What proves it keeps working: Material Cost — FY27 Inflation Headwind Partially Offset by Pricing. It stops working if Petroleum prices sustain above current levels for more than two quarters AND pricing power on decontrolled products fails to achieve 5%+ increases, compressing EBITDA margin below 21%.

Lever 10 · New geographies — BUILDING. FY26 US consolidated (Ipca+Unichem) Rs 1567 Cr (+14% YoY); Ipca's own portfolio: 6-8 new launches planned FY27; Pisgah Labs formulation facility commissioning Q4 FY27. What proves it keeps working: Ipca US Portfolio Inflection (Direct). It stops working if ANDA approvals fall below 3 per year OR Pisgah commissioning slips beyond Q2 FY28, extending the revenue recognition timeline beyond what the thesis requires.

Lever 7 · Consolidation — BUILDING. API revenue Rs 1396 Cr (+10% FY26); FY27 growth 12-13% guided with pricing power from 100% cost pass-through mechanism and favorable product mix. What proves it keeps working: API Business — FY26 Reacceleration, Normalized FY27. It stops working if API pricing competition intensifies (especially in Europe) reducing realizations below cost inflation, or key European/Latin American customers defer orders pushing API growth below 6%.

Sources: our stock research file (19 July 2026) · quarterly results through Jun 26 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Ipca Laboratories Ltd reported ₹2,788 Cr of revenue in the Jun 26 quarter, +20.7% year on year. That is the 12th straight quarter of year-on-year growth. Over 10 years it has compounded at 12.8% a year. The last full year, FY26, came in at ₹9,599 Cr. The last four reported quarters add to ₹10,124 Cr.

Why this happened. Ipca's backward-integrated US model (own APIs into Unichem's commercialization) delivered 25%+ market share within 2 years of first launch. FY26 US consolidated Rs 1567 Cr (+14% YoY). FY27: 6-8 generics pipeline launches planned. Pisgah Labs US formulation facility commissioning targeted Q4 FY27 with meaningful revenue from FY28 onwards. The API facility within Pisgah showing improved order position visible for FY27. This compounds the Unichem recovery: Unichem adds new Ipca-developed molecules onto its existing US commercial infrastructure.

FY26 revenue came in at ₹9,599 Cr (+7.9% on the year), capping 10 years at 12.8% compound. The latest quarter (Jun 26) printed ₹2,788 Cr, +20.7% year on year — the 12th consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +10.5% growth against the decade's 12.8% — the current year is running slower than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +10.6% over the last 4 quarters against +11.0%/yr over the last 8 — stabilising; TTM profit +68.0% vs +57.2%/yr — accelerating.

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Ipca Laboratories Ltd's operating margin is 24.0% in the Jun 26 quarter, +6.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 10.0% to 29.0%. The current quarter sits inside that band.

Why this happened. FY26 domestic formulations grew 10% vs IPM 8.9%, maintaining rank 16 with 2.09% market share. Chronic segment growing 15% vs IPM 12%; specialty segments (CNS, dermatology, urology) growing 17-22% on pain's 13% base. Chronic share at 35% vs market 40% — each 1 percentage point mix shift toward chronic supports the 150 bps annual margin expansion guide. 7000 MRs with 400-500 additions/year for next 2-3 years reinforce the momentum. FY27 guidance: 12% domestic growth decomposed as 1-2% new products, balance from pricing and volume.

The latest quarter's operating margin is 24.0%, +6.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 10.0%–29.0%.

Why the margin moved: operating margin went +6.0 pp year on year while gross margin went +1.4 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Ipca Laboratories Ltd earned ₹424 Cr of net profit in the Jun 26 quarter, +82.0% year on year. It is the 9th consecutive quarter of growth. Full-year FY26 profit was ₹1,184 Cr. The 10-year compound rate is 29.0%. That is 15.2% of the quarter's revenue. The same quarter a year earlier earned ₹233 Cr.

Jun 26 profit was ₹424 Cr, +82.0% year on year — the 9th consecutive quarter of growth. On the full year, FY26 printed ₹1,184 Cr (+50.8%), and the 10-year compound rate is 29.0%.

Why profit moved: revenue contributed +20.7% and the margin +6.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.

Pace comparison, last four quarters: profit +126.9% vs revenue +10.5%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 137% of Ipca Laboratories Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹1,142 Cr of operating cash against ₹1,184 Cr of profit. After ₹929 Cr of capital spending, ₹213 Cr was left as free cash.

FY26: operating cash of ₹1,142 Cr against reported profit of ₹1,184 Cr, leaving free cash of ₹213 Cr after ₹929 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 137% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 137%: the cash cycle stretched 57 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.

Router verdict: the bigger cash user is investment — capital spending ran 3.1× depreciation over three years, so the next section's job is to check what that build-out is buying.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Ipca Laboratories Ltd's cash conversion cycle runs 308 days in FY26, up from 251 days in FY21. Capital spending ran ₹3,682 Cr over the last 3 years. At FY26 sales of ₹9,599 Cr each day of that cycle holds about ₹26.3 Cr, so roughly ₹8,100 Cr sits inside the business at any moment.

FY26: debtors at 77 days, inventory at 353 days — roughly 11.6 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 308 days, looser than FY21's 251.

The full loop: cash goes out to suppliers and production on day 0; stock waits 353 days to sell; customers pay about 77 days after that; and suppliers themselves are paid at 122 days — netting out to the 308-day cycle.

In money terms: at FY26 sales of ₹9,599 Cr, each day of the cycle holds about ₹26.3 Cr — so the 308-day loop keeps roughly ₹8,100 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹3,682 Cr over the last 3 fiscal years against ₹1,173 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹773 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Ipca Laboratories Ltd earns a ROCE of 17% in FY26. That is up from a trough of 5% in FY16. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 12.3% net margin on 0.78× asset turns.

FY26 ROCE is 17%, recovered from a FY16 trough of 5% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY26): 12.3% net margin × 0.78× asset turns × 1.53× balance-sheet leverage ≈ 14.7% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.

The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 5,809% on reported income across 15 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.

Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.

Ipca Laboratories Ltd carries ₹809 Cr of borrowings against ₹8,063 Cr of equity in FY26, a debt-to-equity of 0.10. Operating profit covers the interest bill 25×. Over 5 years borrowings went from ₹265 Cr to ₹809 Cr. Capital spending ran ₹3,682 Cr across the last 3 of those years.

FY26: borrowings of ₹809 Cr against equity of ₹8,063 Cr — a debt-to-equity of 0.10. Operating profit covers the interest bill 25×. Over 5 years borrowings went from ₹265 Cr to ₹809 Cr while capital spending ran ₹3,682 Cr in just the last 3 — part of the build-out is riding on borrowed money.

The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 5,809% on reported income across 15 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Domestic institutions added 3.6 points of Ipca Laboratories Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 37.0% of the company. Promoters moved −1.6 points over the same window, to 44.7%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Domestic institutions: +3.6 points over 8 quarters to 37.0%; Promoters: −1.6 points over 8 quarters to 44.7%; Foreign institutions: −0.1 points over 8 quarters to 10.7%.

Why the register moved: domestic institutions drove it (+3.6 points), absorbed on the other side by promoters (−1.6 points) — steady accumulation by institutions reading the same numbers this page reads.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Ipca Laboratories Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Ipca Laboratories Ltd trades at 32.0× P/E, near the bottom of its own range — cheaper only 31% of the time. Its long-run median P/E is 37.4×, measured across 10.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 32.0× is near the bottom of its own range — cheaper only 31% of the time, against a long-run median of 37.4× measured over 10.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Why the multiple sits where it does: over the past year annual EPS moved +54.7% against a +27.0% price move — earnings outran the price, pushing the multiple DOWN its own range.

The price move, decomposed: over 5y, of the +7.8%/yr price move, ~+6.5%/yr came from earnings growth and ~+1.3 pp from the multiple (expanding); over 10y, of the +20.6%/yr price move, ~+31.5%/yr came from earnings growth and ~−10.9 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.

The PEG ratio and its quarterly curve, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 5,809% on reported income across 15 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.

Stage: Consistent Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Ipca Laboratories Ltd reads as consistent on its fundamental arc. Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROCE at 17.0% and holding. The read is built from 9 quarters across 4 curves, on partial evidence.

Why it matters: steady curves with healthy returns are the compounding setup — the risk is the price, not the business.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.

4-Factor Sector Score

62.0/100 — rank 8 of 44 in Pharma - Formulators · 82% evidence confidence

Ipca Laboratories Ltd scores 62.0 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 8. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 26.6 + 15.8 + 11.1 + 8.5 = 62. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Said versus delivered

What Ipca Laboratories Ltd's management promised, set against what actually arrived — 4 tracked promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.

Unichem Ireland Facility Savings Delayed · 1 June 2026. In the Nov 2025 call, management stated that the closure costs for Unichem's Ireland facility were already settled in Q1 and that the EUR 3.5 to 4 million running overhead would be cut immediately. However, in the Jun 2026 call, management revealed they actually continued operating and incurring EUR 4 to 5 million in overhead for the Ireland facility throughout the entire past financial year (FY26), pushing the realization of these expected savings to FY27 without explaining the execution delay.

Unichem Margin and Growth Outlook · 16 February 2026. Management guided in the November 2025 call that Unichem's margins (around 11%) would remain stable and in line with Q2 levels, citing good US growth of 12%. However, in the February 2026 call, they reported a significant deterioration with margins dropping to 8% and base business growth falling to 2%, attributed to lost high-volume business. Earlier call (Nov 2025): “I think over INR60 crores kind of EBITDA margins they have, which is around 11% or so of the second quarter. So, I think overall, their business margins are expected to remain around what is in line with the second quarter”. Later call (Feb 2026): “Overall, Unichem”.

Unichem Market Share Recovery Timeline · 16 February 2026. In the November 2025 call, management explicitly stated that the business impact seen in Q1 was unlikely to recur in the third and fourth quarters. In a reversal, the February 2026 call admitted that the decline actually started in Q2 and guided that it will likely continue for another one or two quarters. Earlier call (Nov 2025): “So hit which was there in first quarter is not likely to be there in third and fourth quarter.” Later call (Feb 2026): “The decline started in Q2 and will likely continue for one or two more quarters.”

API Business Guidance Doubled · 13 November 2025. Management dramatically increased the full-year FY26 growth guidance for the API segment. In the May 2025 call, growth was projected at only 6-7%, but in the November 2025 call, this forecast was more than doubled to 14-15% without a clear explanation for such a significant upward revision. Earlier call (May 2025): “Around 6%, 7%, Rashmi, not beyond that.” Later call (Nov 2025): “Overall API business of the current financial year is expected to grow around 14% to 15%.”

Every quote above is taken word for word from the company’s own earnings calls.

Frequently asked questions